Canopus SEER: Revolutionizing Network Observability with Real-Time Data and AI Insights
- Canopus SEER is a real-time network observability platform leveraging Agentic-AI for efficient monitoring and data management.
- The platform provides high-quality, real-time insights, enabling proactive network performance management and reducing downtime risks.
- Canopus SEER's patented algorithms contextualize data, enhancing decision-making efficiency for network operations teams.
Canopus SEER: A Groundbreaking Leap in Network Observability
Canopus Networks unveils Canopus SEER, a cutting-edge real-time network observability platform that harnesses the power of Agentic-AI to empower enterprises and carriers in managing vast amounts of monitoring data. This innovative solution emerges from 12 years of research, underpinned by eight patents and over 30 academic publications, addressing a critical challenge in the industry: reactive observability. As Bhaskar Dutta, Chief Product Officer at Canopus Networks, points out, existing network telemetry often suffers from fragmentation and inefficiency, resulting in a reliance on low-fidelity data that generates countless alerts and demands extensive manual investigations.
The Canopus SEER platform addresses this "visibility paradox" by delivering high-quality, real-time data that equips network teams with the necessary insights to act decisively. By deploying high-performance cloud-native eBPF sensors, SEER can extract real-time telemetry data from any network traffic, including encrypted data, with remarkable speed—100 milliseconds—and an impressive capacity of up to 400 Gbps per node. This capability offers unprecedented visibility at the user and application levels, allowing operations teams to better understand their network environments and respond to issues more swiftly.
Underlying the platform's effectiveness are patented algorithms that contextualize billions of real-time flows, creating detailed application and behavioral fingerprints. Professor Vijay Sivaraman, founder and CEO of Canopus Networks, emphasizes the importance of high-quality data ingestion for effective AI-driven observability. He advocates for a radically different approach to achieving observability at scale, positioning Canopus SEER as a revolutionary tool that promises faster, more cost-effective, and efficient decision-making for network operations.
In addition to its impressive technological advancements, Canopus SEER stands out in an industry plagued by reactive approaches to network monitoring. By providing actionable insights in real-time, the platform enables organizations to transition from a reactive to a proactive stance in managing network performance. This shift not only enhances operational efficiency but also significantly reduces the potential for downtime and service disruptions.
As network requirements continue to evolve and become more complex, Canopus SEER represents a timely advancement in network observability. With its innovative features and commitment to high-quality data, it positions itself as a critical resource for enterprises aiming to navigate the complexities of modern networks while maximizing efficiency and minimizing risks.
Related Cashu News

Travere Therapeutics Reports Positive FILSPARI Results and Achieves First Profitable Quarter
Travere Therapeutics (Ticker: TVTX) shows promising advancements in its drug FILSPARI, vital in treating focal segmental glomerulosclerosis (FSGS). Recently, the company released positive long-term da…

PTC Therapeutics Raises $500 Million for Debt Management and Growth in Biopharmaceuticals
PTC Therapeutics (Ticker: PTCT) aims to strengthen its financial position through a recent private placement of $500 million in Convertible Senior Notes due in 2031. This strategic move is intended to…

Insmed Navigates Investor Changes Amid Strong Pipeline and Mixed Analyst Sentiment
Insmed Inc (Ticker: INSM) is in a transformative phase as it navigates recent changes in its investor landscape and the impact on its business model. The company, known for its focus on rare diseases,…

Atossa Therapeutics Raises $4.5 Million to Support Oncology Clinical Development Efforts
Atossa Therapeutics (Ticker: ATOS) successfully finalizes a registered direct offering, generating approximately $4.5 million. This funding is crucial as the company progresses its clinical efforts ai…